Scarica l'app Stockscreener
4.53
4.23%
-0.20
Dopo l'orario di chiusura:
4.47
-0.06
-1.32%
Precedente Chiudi:
$4.73
Aprire:
$4.69
Volume 24 ore:
2.42M
Relative Volume:
1.85
Capitalizzazione di mercato:
$588.82M
Reddito:
$204.17M
Utile/perdita netta:
$-74.00M
Rapporto P/E:
-7.8442
EPS:
-0.5775
Flusso di cassa netto:
$-12.84M
1 W Prestazione:
-3.62%
1M Prestazione:
-2.79%
6M Prestazione:
+7.09%
1 anno Prestazione:
+21.12%
Intervallo 1D:
$4.51
$4.70
Intervallo di 1 settimana:
$4.51
$4.75
Portata 52W:
$3.28
$6.18
Cytek Biosciences Inc Stock (CTKB) Company Profile
Nome
Cytek Biosciences Inc
Settore
Industria
Telefono
(877) 922-9835
Indirizzo
47215 LAKEVIEW BOULEVARD, FREMONT
Compare CTKB vs ABT, MDT, SYK, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CTKB
Cytek Biosciences Inc
|
4.53 | 614.82M | 204.17M | -74.00M | -12.84M | -0.5775 |
ABT
Abbott Laboratories
|
103.36 | 182.09B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
91.62 | 117.54B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
270.01 | 105.63B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
43.10 | 65.16B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.77 | 49.67B | 6.30B | 1.07B | 1.09B | 1.8406 |
Cytek Biosciences Inc Stock (CTKB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-02 | Ripresa | Morgan Stanley | Equal-Weight |
| 2025-05-09 | Downgrade | TD Cowen | Buy → Hold |
| 2025-01-31 | Downgrade | Goldman | Buy → Sell |
| 2023-12-14 | Iniziato | Stephens | Overweight |
| 2023-07-19 | Iniziato | Raymond James | Mkt Perform |
| 2022-01-06 | Ripresa | Piper Sandler | Overweight |
Mostra tutto
Cytek Biosciences Inc Borsa (CTKB) Ultime notizie
Cytek Biosciences, Sysmex Europe Collaborate to Deliver Clinical Flow Cytometry Workflows - marketscreener.com
Sysmex Europe SE And Cytek Biosciences, Inc Collaborate To Expand Access To Advanced Clinical Flow Cytometry - marketscreener.com
Sysmex Europe SE and Cytek Biosciences Announce Strategic Collaboration to Expand Clinical Flow Cytometry Access Across Europe - Quiver Quantitative
Sysmex Europe and Cytek® Biosciences Collaborate to Expand Access to Advanced Clinical Flow Cytometry - Yahoo Finance
Cytek’s (CTKB) Instruments Keep Selling While Losses Keep Growing - Yahoo Finance
Cytek Biosciences to Showcase Spectral Flow Cytometry Solutions at ESCCA 2026 and ICCS 2026 - quiverquant.com
Cytek Biosciences Showcases Advanced Spectral Flow Cytometry Solutions At Escca and Iccs - marketscreener.com
Cytek Biosciences (CTKB) officer plans $146K share sale - Stock Titan
Cytek Biosciences stock holds near recent levels as investor conferences approach - AD HOC NEWS
Cytek Biosciences to Participate in Upcoming Investor Conferences - GlobeNewswire
Cytek Owes Beckman Coulter $56 Million at Patent Jury Trial (2) - Bloomberg Law News
Cytek (CTKB) Earnings Report: EPS Clears the Reported Estimate in Latest Trading; Price Reaction: Shares Finish 3.22% Up in the Latest SessionPre-Announcement Alert - vinanet.vn
Cytek Hit With $56M Verdict For Infringing Cell-Sorting Patent - Law360
Cytek Biosciences wins on three of four patent claims - Investing.com
Cytek Biosciences wins on three of four patent claims By Investing.com - Investing.com Nigeria
Cytek owes Beckman Coulter $56 mln in cell-analysis patent case, US jury says - Reuters
Jury Finds in Cytek’s Favor on Three of Four Asserted Claims; Company to Challenge Remaining Finding - marketscreener.com
Cytek products remain available worldwide after jury awards $36M in royalties - Stock Titan
Cytek Biosciences CFO William D. McCombe Executes RSU Vesting and Tax Withholding Transactions - Kalkine Media
Cytek Biosciences Director Glenn P. Muir Converts 3,086 RSUs to Common Stock on August 18, 2026 - Kalkine Media
Cytek Biosciences (CTKB) CEO gets 120K shares, surrenders some for taxes - Stock Titan
Cytek Biosciences (NASDAQ: CTKB) director gains 3,086 no-cost shares - Stock Titan
Cytek Biosciences (CTKB) director now holds 28,499 shares - Stock Titan
Cytek Biosciences (CTKB) CTO gets 33,270 shares, surrenders some for taxes - Stock Titan
Cytek (CTKB) Quarterly Figures: EPS Prints Above Forecast in the Latest Session; Stock Move: Shares Finish 0.96% HigherEstimate Dispersion - vinanet.vn
Cytek Biosciences CEO Wenbin Jiang Completes RSU Vesting and Tax Withholding Share Surrender - Kalkine Media
Cytek Biosciences Balances Growth With Profit Pressures - TipRanks
Cytek (CTKB) Q2 2026 Earnings Call Transcript - AOL.com
Cytek Biosciences (CTKB) awards 241,416 RSUs and 127,118 options to top lawyer - Stock Titan
Cytek Biosciences: Recurring Revenue Reaches 35% Of Sales As Installed Base Approaches 4,000 Instruments - Pulse 2.0
Cytek Biosciences launches Aurora Evo system to drive high-throughput research and small particle detection - Traders Union
Promising Penny Stocks To Consider In August 2026 - simplywall.st
Cytek Biosciences (NASDAQ:CTKB) Trading 8.5% HigherShould You Buy? - MarketBeat
Cytek Biosciences, Inc. (8EQ.MU) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Analysts Offer Insights on Healthcare Companies: Zimmer Biomet Holdings (ZBH), Cytek Biosciences (CTKB) and Sight Sciences (SGHT) - The Globe and Mail
Cytek Biosciences, Inc. (CTKB) interactive stock chart – Yahoo Finance - Yahoo Finance Singapore
Cytek Biosciences (CTKB) holders report over 7% stakes in Schedule 13G/A - Stock Titan
Cytek Biosciences, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Morgan Stanley Maintains Cytek Biosciences(CTKB.US) With Hold Rating, Cuts Target Price to $5 - Moomoo
TD Cowen Maintains Cytek Biosciences(CTKB.US) With Hold Rating, Maintains Target Price $5 - Moomoo
Cytek Biosciences Reports Second Quarter 2026 Financial Results - The Manila Times
Cytek Biosciences Inc (CTKB) (Q2 2026) Earnings Call Highlights: Revenue Up 6% to $48. ... - Yahoo! Finance Canada
Cytek Biosciences Q2 2026 Earnings Report: Financial Highlights, Revenue Growth, and Investor Insights - Minichart
CTKB Looks 28.3% Undervalued on GF Value™ Despite Unprofitable S - GuruFocus
Cytek Biosciences (NASDAQ:CTKB) Posts Earnings Results, Hits Estimates - MarketBeat
Cytek Biosciences Q2 Earnings Call Highlights - MarketBeat
Cytek Biosciences, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Cytek Biosciences earnings missed, revenue fell short of estimates - Investing.com
Earnings call transcript: Cytek Biosciences posts q2 2026 revenue growth, shares fall - Investing.com Nigeria
Cytek Biosciences, Inc. (CTKB) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Cytek Biosciences (CTKB) Releases Q2 2026 Earnings: Revenue Growth but EPS Miss - Quiver Quantitative
Cytek Biosciences Inc Azioni (CTKB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.29%
0.75%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):